{"product_id":"biolegend-329702","title":"Biolegend, 329702, Purified anti-human CD274 (B7-H1, PD-L1) Antibody, 100μg","description":"\u003cp\u003eCD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: African Green, Baboon, Cynomolgus, Rhesus\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nImmunogen: Full length human PD-L1\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography.\u003cbr\u003e\nConcentration: 0.5 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C.\u003cbr\u003e\nApplication: FC - Quality tested IHC-P - Verified Block - Reported in the literature, not verified in house\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunohistochemical staining on formalin-fixed paraffin-embedded tissue sections, the suggested use of this reagent is 5.0 - 10 µg per ml. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nApplication Notes: Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5. Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1. The Ultra-LEAF™ purified antibody (Endotoxin \u0026lt; 0.01 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest. Clone 29E.2A3 does not work in Western blot applications7.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block) Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block) Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block) Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed Haile, S et al. 2013. J. Immunol. 191:2829. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.\u003cbr\u003e\nProduct Citations: Zhou B, et al. 2020. Theranostics. 10:6530. PubMed Niu Q, et al. 2022. Proc Natl Acad Sci U S A. 119:e2213236119. PubMed Zhang G, et al. 2023. J Immunother Cancer. 11:. PubMed Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed Alpert A, et al. 2022. Cell Syst. 13:71. PubMed McCarthy EE, et al. 2022. Cell Rep. 39:110815. PubMed Qiao J, et al. 2022. PLoS One. 17:e0277956. PubMed Yonemitsu K, et al. 2022. Sci Rep. 12:12007. PubMed Barsoum I, et al. 2014. Cancer Res. 74:665. PubMed Hamanishi J, et al. 2015. J Clin Oncol. 101200\/JCO2015623397. PubMed Komohara Y, et al. 2018. J Clin Exp Hematop. 58:152. PubMed Parackova Z, et al. 2020. Sci Rep. 0.759027778. PubMed Paterson K, et al. 2022. IEEE Open J Eng Med Biol. 3:86. PubMed Juttukonda LJ, et al. 2017. Cell Host Microbe. 22:531. PubMed Heesters BA, et al. 2021. J Exp Med. 218:. PubMed Hsu DC, et al. 2018. Clin Infect Dis. 67:437. PubMed Nolan E, et al. 2017. Sci Transl Med. 9:eaal4925. PubMed Hartley GP, et al. 2018. Cancer Immunol Res. 6:1260. PubMed Lee SWL, et al. 2018. Front Immunol. 8:1064. PubMed Zeller AN, et al. 2021. Eur Cell Mater. 41:603. PubMed Agrawal N, et al. 2018. Front Immunol. 2.053472222. PubMed Li C, et al. 2016. Nat Commun. 7:12632. PubMed Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed Kim DH, et al. 2019. Exp Mol Med. 51:94. PubMed Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed Baruah P, et al. 2019. Front Immunol. 10:1644. PubMed Schwabenland M, et al. 2021. Immunity. . PubMed Salvany‐Celades M et al. 2019. Cell Rep. 27(9):2537-2547 . PubMed Acheampong E, et al. 2019. Cancers (Basel). 11. PubMed Hang Q, et al. 2020. Zhongguo Fei Ai Za Zhi. 1.539583333. PubMed Saber MM, et al. 2022. Antibodies (Basel). 11:. PubMed Kim MH, et al. 2018. Cancer Immunol Res. 0.427083333. PubMed Kennedy-Darling J, et al. 2021. Eur J Immunol. 51:1262. PubMed Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed Wang Y, et al. 2019. Sci Rep. 9:566. PubMed Burr ML, et al. 2017. Nature. 549:101. PubMed Janse van Rensburg HJ, et al. 2018. Cancer Res. 78:1457. PubMed Enyindah-Asonye G, et al. 2019. Front Immunol. 10:511. PubMed Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed Hwang HJ, et al. 2021. Immun Inflamm Dis. 9:274. PubMed Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed\u003cbr\u003e\nRRID: AB_940370 (BioLegend Cat. No. 329701) AB_940372 (BioLegend Cat. No. 329702)\u003cbr\u003e\nDistribution: T cells, B cells, NK cells, monocytes\/macrophages, granulocytes and dendritic cells\u003cbr\u003e\nFunction: CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.\u003cbr\u003e\nLigand\/Receptor: PD-1 (PDCD1)\u003cbr\u003e\nCell Type: B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells\u003cbr\u003e\nBiology Area: Cancer Biomarkers, Costimulatory Molecules, Immunology\u003cbr\u003e\nMolecular Family: Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors\u003cbr\u003e\nAntigen References: 1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.\u003cbr\u003e\nGene ID: 29126\u003cbr\u003e\nUniProt: View information about CD274 on UniProt.org\u003cbr\u003e\nClone: 29E.2A3\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)\u003cbr\u003e\nIsotype: Mouse IgG2b, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46866546229417,"sku":"329702","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-329702","provider":"Iright","version":"1.0","type":"link"}